Indiana is currently home to 1191 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Desara ® One Single Incision Sling 522 Study
NCT04772131
Recruiting
A post-market study to compare the safety and effectiveness of the Desara® One Single Incision Sling (SIS), when compared to that of an FDA cleared transobturator sling over a period of 36 months.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2023
Locations: CMB Research, LLC, Newburgh, Indiana
Conditions: Stress Urinary Incontinence
Register for Updates
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
NCT04314375
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/05/2023
Locations: Bausch Health Site 003, Indianapolis, Indiana
Conditions: Ulcerative Colitis
Register for Updates
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
NCT04892472
Recruiting
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to t... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/04/2023
Locations: Parkview Research Center, Fort Wayne, Indiana
Conditions: Non-small Cell Lung Cancer
Register for Updates
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
NCT04054310
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Indiana University Health, Indianapolis, Indiana
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Mobile Peer Support for OUD Recovery
NCT05405712
Recruiting
The COVID-19 pandemic puts individuals recovering from opioid use disorders (OUDs), an already vulnerable population, at increased risk of overdose due to decreased access to treatment, decreased social support, and increased psychosocial stress. This proposal will test the efficacy of a promising mobile app-based peer support program, compared to usual care, in increasing recovery capital, improving retention in treatment, and reducing psychosocial adverse effects, among a national sample of pe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Opioid Use Disorder
Register for Updates
Promoting the Well Being of Caregivers Via Telehealth
NCT05999448
Recruiting
The goal of this clinical trial is to learn which types of telehealth-based treatments best fit the needs of caregivers of people with rare neurogenetic conditions. The main questions it plans to answer are: * Which telehealth support programs best meet the needs of rare disorder caregivers? * How can individuals be matched to support programs that are right for them? What aspects of an individual (e.g., demographics, mental health symptoms, family characteristics, lifestyle) predict whether tr... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/11/2023
Locations: Purdue University, West Lafayette, Indiana
Conditions: Caregivers, Parents
Register for Updates
Spironolactone in CKD Enabled by Chlorthalidone: PILOT
NCT05222191
Recruiting
Highly prevalent among patients with chronic kidney disease (CKD) and poorly controlled blood pressure (BP), is a modifiable risk factor to abrogate both kidney failure progression and cardiovascular (CV) disease. Spironolactone (SPL), a mineralocorticoid receptor antagonist, is widely used to treat resistant hypertension, however one of the most common side effects is an increase of serum potassium (K). This side effect occurs frequently in those who suffer from CKD. Alternatively, chlorthalido... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
08/11/2023
Locations: Richard L Roudebush VA Medical Center, Indianapolis, Indiana
Conditions: Renal Insufficiency, Chronic Hypertension
Register for Updates
Terumo Aortic Global Endovascular Registry
NCT04246463
Recruiting
Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: Ascension St. Vincent Heart Center, Indianapolis, Indiana
Conditions: Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Register for Updates
Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE TAVR)
NCT04827238
Recruiting
The DISCORDANCE TAVR study will determine the discordance between echocardiography-derived and invasive transaortic gradients, as determined by a consistent and reproducible technique (Standardized Invasive Hemodynamics) post-TAVR.
Gender:
ALL
Ages:
All
Trial Updated:
06/06/2023
Locations: eCommunity, Indianapolis, Indiana
Conditions: Aortic Stenosis, Aortic Valve Stenosis
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
04/05/2023
Locations: Galderma Investigational Site #8142, Indianapolis, Indiana
Conditions: Moderate-to-Severe Atopic Dermatitis
Register for Updates
Comparing the Adaptation of Commercial Milk and A2 Milk in Lactose Maldigesters
NCT05669274
Recruiting
Cow's milk contains two types of β-casein: A1 and A2. It is evident from human clinical trials that milk with A1 protein produces more hydrogen and symptoms of lactose intolerance. A pro-inflammatory μ-opioid peptide BCM-7 is released from A1 but not from A2. Milk containing A1 β-casein produced more inflammatory markers than A2 β-casein. This is a double-blinded, randomized, controlled trial conducted to determine if there are changes in inflammatory markers following two weeks of milk feeding,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/27/2023
Locations: Purdue University, West Lafayette, Indiana
Conditions: Lactose Intolerance
Register for Updates